biostudies-literatureWang XNational Nature Science Foundation of China104https://www.ebi.ac.uk/biostudies/studies/S-EPMC9482291biostudies-literatureUnknown15(1)<h4>Background</h4>Ovarian malignant mesoderm mixed tumor (OMMMT) is a rare clinical entity. To provide reference for the treatment and prognosis of OMMMT, we analyzed the clinical features, pathology and molecular biology characteristic of published cases.<h4>Methods</h4>The English and Chinese reported cases of OMMMT were selected from PubMed, Clinical Trials.gov and CNKI database from 2000 to December 15th, 2021 following the PRISMA guidelines.<h4>Results</h4>A total of 63 literatures including 199 OMMMT cases were included. The average age of patients at diagnosis was 56.46 years, the highest incidence age was 60-65 years, and 82% of them were menopausal women. Most patients were diagnosed in FIGO III stage (59.64%). The most common symptom of OMMMT was abdominal pain (60.5%). 61.6% ofJournal of ovarian researchThe clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.PMC948229181903948, 81873330Wang SYao SShi WWang XMa KfalseThe clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.<h4>Background</h4>Ovarian malignant mesoderm mixed tumor (OMMMT) is a rare clinical entity. To provide reference for the treatment and prognosis of OMMMT, we analyzed the clinical features, pathology and molecular biology characteristic of published cases.<h4>Methods</h4>The English and Chinese reported cases of OMMMT were selected from PubMed, Clinical Trials.gov and CNKI database from 2000 to December 15th, 2021 following the PRISMA guidelines.<h4>Results</h4>A total of 63 literatures including 199 OMMMT cases were included. The average age of patients at diagnosis was 56.46 years, the highest incidence age was 60-65 years, and 82% of them were menopausal women. Most patients were diagnosed in FIGO III stage (59.64%). The most common symptom of OMMMT was abdominal pain (60.5%). 61.6% of2022-01-01T00:00:00Z2022 Sep2025-06-01T02:30:50.383Z2024-11-15T06:56:41.928ZS-EPMC94822913611455110.1186/s13048-022-01037-6